Product image
Product image
Product image

Tirzepatide (Pack of 10)

CA$349.00

CA$699.0050% off

Volume

Quantity

X+
  1. Not for human consumption

  2. Not to be used on animals.

  3. For lab research purposes only

  4. The product is 99% pure

  5. Crystalized visible powder or looks like an empty bottle: depends on available inventory

  6. Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes[10][13][14][15] and for weight loss.[11][16] Tirzepatide is administered via subcutaneous injections (under the skin).[10][13] It is sold under the brand names Mounjaro for diabetes treatment,[10] and Zepbound for weight loss.[11]

    Tirzepatide

    Clinical data

    Pronunciation

    /tɜːrˈzɛpətaɪd/ tur-ZEP-ə-tyde

    Trade names

    Mounjaro, Zepbound

    Other names

    LY3298176, GIP/GLP-1 RA

    AHFS/Drugs.com

    Monograph

    MedlinePlus

    a622044

    License data

    Pregnancy category

    Routes of administration

    Subcutaneous

    Drug class

    Antidiabetic, GLP-1 receptor agonist

    ATC code

    Legal status

    Legal status

    Pharmacokinetic data

    Bioavailability

    80%

    Protein binding

    Albumin

    Metabolism

    Proteolytic cleavage, β-oxidation of fatty diacid section and amide hydrolysis

    Elimination half-life

    5 days

    Excretion

    Urine and faeces

    Identifiers

    CAS Number

    PubChem CID

    IUPHAR/BPS

    DrugBank

    ChemSpider

    UNII

    KEGG

    ChEBI

    ChEMBL

    Chemical and physical data

    Formula

    C225H348N48O68

    Molar mass

    4813.527 g·mol−1

    3D model (JSmol)

    show

    show

    Tirzepatide is a gastric inhibitory polypeptide receptor and GLP-1 receptor agonist.[11] The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.[10][13][17]

    Tirzepatide was approved for treatment of diabetes in the United States in May 2022,[10][13] in the European Union in September 2022,[12] in Canada in November 2022,[18] and in Australia in December 2022.[2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[19][20] It was approved by the FDA for weight loss in November 2023.[16][21] In November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for tirzepatide to include treatment for weight loss.[8][22]

https://en.m.wikipedia.org/wiki/Tirzepatide